NASDAQ:FHTX

Foghorn Therapeutics Competitors

$11.50

-0.28 (-2.38 %)

(As of 04/16/2021 04:00 PM ET)

Add

Compare

Today's Range

$11.20

Now: $11.50▼

$12.05

50-Day Range

$11.78

MA: $13.57▼

$16.87

52-Week Range

$11.65

Now: $11.50▼

$28.26

Volume50,582 shs

Average Volume98,705 shs

Market Capitalization$423.40 million

P/E RatioN/A

Dividend YieldN/A

BetaN/A

Foghorn Therapeutics (NASDAQ:FHTX) Vs. SUPN, MYOV, HRTX, ADCT, HRMY, and GBIO

Should you be buying FHTX stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Foghorn Therapeutics, including Supernus Pharmaceuticals (SUPN), Myovant Sciences (MYOV), Heron Therapeutics (HRTX), ADC Therapeutics (ADCT), Harmony Biosciences (HRMY), and Generation Bio (GBIO).

Foghorn Therapeutics vs. Supernus Pharmaceuticals Stock

Supernus Pharmaceuticals (NASDAQ:SUPN) and Foghorn Therapeutics (NASDAQ:FHTX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, valuation, risk, institutional ownership, earnings, analyst recommendations and dividends.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Supernus Pharmaceuticals and Foghorn Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Supernus Pharmaceuticals	0	0	2	0	3.00
Foghorn Therapeutics	0	0	4	0	3.00

Supernus Pharmaceuticals presently has a consensus target price of $37.50, suggesting a potential upside of 18.30%. Foghorn Therapeutics has a consensus target price of $24.6667, suggesting a potential upside of 114.49%. Given Foghorn Therapeutics' higher probable upside, analysts clearly believe Foghorn Therapeutics is more favorable than Supernus Pharmaceuticals.

Insider and Institutional Ownership

96.1% of Supernus Pharmaceuticals shares are held by institutional investors. 6.6% of Supernus Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Supernus Pharmaceuticals and Foghorn Therapeutics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Supernus Pharmaceuticals	27.09%	20.02%	9.67%
Foghorn Therapeutics	N/A	N/A	N/A

Valuation & Earnings

This table compares Supernus Pharmaceuticals and Foghorn Therapeutics' gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Supernus Pharmaceuticals	$392.76 million	4.27	$113.06 million	$2.10	15.10
Foghorn Therapeutics	N/A	N/A	N/A	N/A	N/A

Supernus Pharmaceuticals has higher revenue and earnings than Foghorn Therapeutics.

Summary

Supernus Pharmaceuticals beats Foghorn Therapeutics on 6 of the 8 factors compared between the two stocks.

Foghorn Therapeutics vs. Myovant Sciences Stock

Myovant Sciences (NYSE:MYOV) and Foghorn Therapeutics (NASDAQ:FHTX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, valuation, risk, institutional ownership, earnings, analyst recommendations and dividends.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Myovant Sciences and Foghorn Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Myovant Sciences	0	3	3	0	2.50
Foghorn Therapeutics	0	0	4	0	3.00

Myovant Sciences presently has a consensus target price of $31.1667, suggesting a potential upside of 72.57%. Foghorn Therapeutics has a consensus target price of $24.6667, suggesting a potential upside of 114.49%. Given Foghorn Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Foghorn Therapeutics is more favorable than Myovant Sciences.

Insider and Institutional Ownership

33.8% of Myovant Sciences shares are held by institutional investors. 3.9% of Myovant Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Myovant Sciences and Foghorn Therapeutics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Myovant Sciences	N/A	N/A	-201.20%
Foghorn Therapeutics	N/A	N/A	N/A

Valuation & Earnings

This table compares Myovant Sciences and Foghorn Therapeutics' gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Myovant Sciences	N/A	N/A	$-288,990,000.00	($3.37)	-5.36
Foghorn Therapeutics	N/A	N/A	N/A	N/A	N/A

Summary

Foghorn Therapeutics beats Myovant Sciences on 4 of the 6 factors compared between the two stocks.

Foghorn Therapeutics vs. Heron Therapeutics Stock

Heron Therapeutics (NASDAQ:HRTX) and Foghorn Therapeutics (NASDAQ:FHTX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, valuation, risk, institutional ownership, earnings, analyst recommendations and dividends.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Heron Therapeutics and Foghorn Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Heron Therapeutics	0	1	4	0	2.80
Foghorn Therapeutics	0	0	4	0	3.00

Heron Therapeutics presently has a consensus target price of $26.00, suggesting a potential upside of 45.50%. Foghorn Therapeutics has a consensus target price of $24.6667, suggesting a potential upside of 114.49%. Given Foghorn Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Foghorn Therapeutics is more favorable than Heron Therapeutics.

Insider and Institutional Ownership

99.0% of Heron Therapeutics shares are held by institutional investors. 12.9% of Heron Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Heron Therapeutics and Foghorn Therapeutics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Heron Therapeutics	-216.18%	-65.06%	-49.14%
Foghorn Therapeutics	N/A	N/A	N/A

Valuation & Earnings

This table compares Heron Therapeutics and Foghorn Therapeutics' gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Heron Therapeutics	$145.97 million	11.19	$-204,750,000.00	($2.50)	-7.15
Foghorn Therapeutics	N/A	N/A	N/A	N/A	N/A

Foghorn Therapeutics has lower revenue, but higher earnings than Heron Therapeutics.

Summary

Foghorn Therapeutics beats Heron Therapeutics on 5 of the 8 factors compared between the two stocks.

Foghorn Therapeutics vs. ADC Therapeutics Stock

ADC Therapeutics (NYSE:ADCT) and Foghorn Therapeutics (NASDAQ:FHTX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, valuation, risk, institutional ownership, earnings, analyst recommendations and dividends.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for ADC Therapeutics and Foghorn Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ADC Therapeutics	0	1	4	0	2.80
Foghorn Therapeutics	0	0	4	0	3.00

ADC Therapeutics presently has a consensus target price of $47.50, suggesting a potential upside of 103.95%. Foghorn Therapeutics has a consensus target price of $24.6667, suggesting a potential upside of 114.49%. Given Foghorn Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Foghorn Therapeutics is more favorable than ADC Therapeutics.

Insider and Institutional Ownership

40.9% of ADC Therapeutics shares are held by institutional investors. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares ADC Therapeutics and Foghorn Therapeutics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ADC Therapeutics	N/A	N/A	N/A
Foghorn Therapeutics	N/A	N/A	N/A

Valuation & Earnings

This table compares ADC Therapeutics and Foghorn Therapeutics' gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ADC Therapeutics	$2.34 million	685.68	$-116,480,000.00	($2.36)	-9.87
Foghorn Therapeutics	N/A	N/A	N/A	N/A	N/A

Foghorn Therapeutics has lower revenue, but higher earnings than ADC Therapeutics.

Foghorn Therapeutics vs. Harmony Biosciences Stock

Harmony Biosciences (NASDAQ:HRMY) and Foghorn Therapeutics (NASDAQ:FHTX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, valuation, risk, institutional ownership, earnings, analyst recommendations and dividends.

Profitability

This table compares Harmony Biosciences and Foghorn Therapeutics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Harmony Biosciences	N/A	N/A	N/A
Foghorn Therapeutics	N/A	N/A	N/A

Valuation & Earnings

This table compares Harmony Biosciences and Foghorn Therapeutics' gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Harmony Biosciences	N/A	N/A	N/A	N/A	N/A
Foghorn Therapeutics	N/A	N/A	N/A	N/A	N/A

Insider and Institutional Ownership

50.2% of Harmony Biosciences shares are held by institutional investors. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Harmony Biosciences and Foghorn Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Harmony Biosciences	0	0	3	0	3.00
Foghorn Therapeutics	0	0	4	0	3.00

Harmony Biosciences presently has a consensus target price of $51.6667, suggesting a potential upside of 83.54%. Foghorn Therapeutics has a consensus target price of $24.6667, suggesting a potential upside of 114.49%. Given Foghorn Therapeutics' higher probable upside, analysts clearly believe Foghorn Therapeutics is more favorable than Harmony Biosciences.

Summary

Foghorn Therapeutics beats Harmony Biosciences on 2 of the 3 factors compared between the two stocks.

Foghorn Therapeutics vs. Generation Bio Stock

Generation Bio (NASDAQ:GBIO) and Foghorn Therapeutics (NASDAQ:FHTX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

Profitability

This table compares Generation Bio and Foghorn Therapeutics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Generation Bio	N/A	N/A	N/A
Foghorn Therapeutics	N/A	N/A	N/A

Valuation and Earnings

This table compares Generation Bio and Foghorn Therapeutics' gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Generation Bio	N/A	N/A	N/A	N/A	N/A
Foghorn Therapeutics	N/A	N/A	N/A	N/A	N/A

Insider and Institutional Ownership

63.3% of Generation Bio shares are held by institutional investors. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of recent recommendations for Generation Bio and Foghorn Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Generation Bio	0	0	6	0	3.00
Foghorn Therapeutics	0	0	4	0	3.00

Generation Bio presently has a consensus target price of $40.60, suggesting a potential upside of 43.46%. Foghorn Therapeutics has a consensus target price of $24.6667, suggesting a potential upside of 114.49%. Given Foghorn Therapeutics' higher probable upside, analysts clearly believe Foghorn Therapeutics is more favorable than Generation Bio.

Summary

Generation Bio beats Foghorn Therapeutics on 2 of the 3 factors compared between the two stocks.